52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B

Piratvisuth, Teerha; Komolmit, Piyawat; Tanwandee, Tawesak; Sukeepaisarnjaroen, Wattana; Chan, Henry L. Y.; Pessôa, Mário G.; Fassio, Eduardo; Ono, Suzane K.; Bessone, Fernando; Daruich, Jorge; Zeuzem, Stefan; Cheinquer, Hugo; Pathan, Rashidkhan; Dong, Yuhong; Trylesinski, Aldo
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response. The efficacy and safety of this approach applied to telbivudine treatment has not been investigated. Methods: A multinational, phase IV, single-arm open-label study (ClinicalTrials.gov ID NCT00651209) was undertaken in HBeAg-positive, nucleoside-naive adult patients with chronic hepatitis B. Patients received telbivudine (600 mg once-daily) for 24 weeks, after which those with undetectable serum HBV DNA (<300 copies/mL) continued to receive telbivudine alone while those with detectable DNA received telbivudine plus tenofovir (300 mg once-daily). Outcomes were assessed at Week 52. Results: 105 patients commenced telbivudine monotherapy, of whom 100 were included in the efficacy analysis. Fifty-five (55%) had undetectable HBV DNA at Week 24 and continued telbivudine monotherapy; 45 (45%) received tenofovir intensification. At Week 52, the overall proportion of undetectable HBV DNA was 93% (93/100) by last-observation-carried-forward analysis (100% monotherapy group, 84% intensification group) and no virologic breakthroughs had occurred. ALT normalization occurred in 77% (87% monotherapy, 64% intensification), HBeAg clearance in 43% (65% monotherapy, 16% intensification), and HBeAg seroconversion in 39% (62% monotherapy, 11% intensification). Six patients had HBsAg clearance. Myalgia was more common in the monotherapy group (19% versus 7%). No decrease in the mean glomerular filtration rate occurred in either treatment group at Week 52. Conclusions: Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B. Trial Registration: ClinicalTrials.gov NCT00651209


Related Articles

  • Gilead Announces Positive 5-Year Data Showing Effect of Viread on Liver Fibrosis and Cirrhosis Caused by Chronic Hepatitis B.  // Biomedical Market Newsletter;11/9/2011, Vol. 21, p166 

    The article reports on the result of the five-year data from the open-label phase of two pivotal Phase 3 clinical trial of Gilead Sciences Inc., which evaluates the efficacy of Viread for the treatment of chronic hepatitis B virus (HBV) infection. It mentions that results have shown that Viread...

  • Phase IIIb Comparison of BARACLUDE (entecavir) Monotherapy Versus BARACLUDE Plus Tenofovir Combination Shows No Statistical Difference Between Study Arms.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p541 

    The article presents results on the Phase IIIb clinical trial of Bristol-Myers Squibb Co. which compares BARACLUDE monotherapy versus BARACLUDE plus tenofovir in 2011. Serious adverse events (SAEs) in the study were reported in 7.1% of patients with chronic hepatitis B in the BARACLUDE plus...

  • Real-World Experiences with Tenofovir Disoproxil Fumarate: Is this the "B-Ticket"? Terrault, Norah; Terrault, Norah A // Digestive Diseases & Sciences;Oct2016, Vol. 61 Issue 10, p2770 

    No abstract available.

  • Continuous Ultrafiltration in Acute Decompensated Heart Failure: Current Issues and Future Directions. Marenzi, Giancarlo; Morpurgo, Marco; Agostoni, Piergiuseppe // American Journal of Cardiovascular Drugs;Apr2015, Vol. 15 Issue 2, p103 

    Most patients hospitalized for acutely decompensated heart failure (ADHF) present with symptoms and signs of volume overload, which are also associated with high rates of death and re-hospitalization. Several studies have investigated the possible use of extracorporeal ultrafiltration in the...

  • Why is proteinuria such an important risk factor for progression in clinical trials? Jerums, George; Panagiotopoulos, Sianna; Isalamandris, Con; Allen, Terri J.; Gilbert, Richard E.; Comper, Wayne D. // Kidney International Supplement;Dec1997, Issue 63, pS87 

    There are strong reasons to justify the concept that proteinuria is a major risk factor for progression in clinical trials. The evidence is strongest where therapeutic intervention has been focused on established renal disease, when changes in albumin excretion rate (AER) and glomerular...

  • Measurement of glomerular filtration rate. Gaspari, Flavio; Perico, Norberto; Remuzzi, Giuseppe // Kidney International Supplement;Dec1997, Issue 63, pS151 

    Glomerular filtration rate (GFR) is the standard measure of renal function and is critical for the diagnosis and management of renal diseases. Rigorous assessment of GFR requires the measurement of renal clearance of an exogenous marker that is freely filtered by the kidney, and that does not...

  • The impact of ProFiL program on the progression of chronic kidney disease (CKD) and its risk factors: an interim analysis. Beaunoyer, S.; Dupuis, S.; Dumoulin-Charette, A.; Mouchbahani, M.; Daigneault, A. M.; Lord, A.; Bell, R.; Letendre, S.; Clément, V.; Guay, M.; Ricard, S.; Jouini, G.; Azar, J.; Quintana Barcena, P.; Martin, E.; Berbiche, D.; Lalonde, L. // Journal of Population Therapeutics & Clinical Pharmacology;2014, Vol. 21 Issue 1, pe126 

    Background: A clinical trial is ongoing to evaluate ProFiL, a training-and-communication network program in nephrology for community pharmacists. The objective of this analysis is to evaluate the relevance of increasing its sample size to evaluate the impact of ProFiL on the progression of CKD...

  • Timing of start of dialysis in diabetes mellitus patients: a systematic literature review. Nacak, Hakan; Bolignano, Davide; Van Diepen, Merel; Dekker, Friedo; Van Biesen, Wim // Nephrology Dialysis Transplantation;Feb2016, Vol. 31 Issue 2, p306 

    Background. Diabetes mellitus is a frequent cause of the need for renal replacement therapy (RRT). Historically, RRT was started earlier in patients with diabetes, in an attempt to prevent complications of uraemia and diabetes. We did a systematic review to find support for this earlier start of...

  • Con: STOP immunosuppression in IgA nephropathy. Rauen, Thomas; Eitner, Frank; Fitzner, Christina; Floege, Jürgen // Nephrology Dialysis Transplantation;Nov2016, Vol. 31 Issue 11, p1771 

    A comprehensive supportive therapy approach constitutes the mainstay treatment of IgA nephropathy (IgAN) patients. In our recent Supportive versus immunosuppressive Therapy Of Progressive IgA Nephropathy (STOP-IgAN) trial, we systematically selected for patients at high risk of a progressive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics